A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

Study Summary

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

Conditions

Acromegaly

Interventions / Drugs

Paltusotine Placebo

View on ClinicalTrials.gov ↗

Sponsor

CRNX

Crinetics Pharmaceuticals

Endocrinology

D39/100

Study Details

Enrollment111 participants

Primary Completion—

Lead SponsorCrinetics Pharmaceuticals Inc.

Data Retrieved2026-04-11 04:10:51.260370+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.